검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | REGN668 |
Overview Company | Regeneron Pharmaceuticals |
Overview Modality | ANTIBODY |
Overview Target | Healthy |
Overview Indication | Healthy |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | blocks the IL4/IL13 pathway by targeting the receptor |
MoA Biomarker | biomarkers of allergic inflammation in human lung tissue ex-vivo but no airway hyperresponsiveness |
PK/PD Species | NHP, Human |
PK/PD Animal (cat.) | Human, NHP |
PK/PD Experiment | PD |
Toxicology Species | NHP, Human |
Toxicology Animal (cat.) | Human, NHP |
Toxicology Major finding | Dupilumab for the treatment of asthma.. Dupilumab (REGN668/SAR231893), produced by a collaboration between Regeneron and Sanofi, is a monoclonal antibody currently in phase III for moderate-to-severe asthma. Dupilumab is directed against the α-subunit of the interleukin (IL)-4 receptor and blocks the IL-4 and IL-13 signal transduction. Areas covered: Pathophysiological role of IL-4 and IL-13… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 0.45% |
Clinical ORR | -0.45 |
Clinical Result source | ClinicalTrials.gov NCT02912468 |
Clinical Data Tier / Score | A · 27 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | REGN668 |
Overview Company | Regeneron Pharmaceuticals |
Overview Modality | ANTIBODY |
Overview Target | Healthy |
Overview Indication | Healthy |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | blocks the IL4/IL13 pathway by targeting the receptor |
MoA Biomarker | biomarkers of allergic inflammation in human lung tissue ex-vivo but no airway hyperresponsiveness |
PK/PD Species | NHP, Human |
PK/PD Animal (cat.) | Human, NHP |
PK/PD Experiment | PD |
Toxicology Species | NHP, Human |
Toxicology Animal (cat.) | Human, NHP |
Toxicology Major finding | Dupilumab for the treatment of asthma.. Dupilumab (REGN668/SAR231893), produced by a collaboration between Regeneron and Sanofi, is a monoclonal antibody currently in phase III for moderate-to-severe asthma. Dupilumab is directed against the α-subunit of the interleukin (IL)-4 receptor and blocks the IL-4 and IL-13 signal transduction. Areas covered: Pathophysiological role of IL-4 and IL-13… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 0.45% |
Clinical ORR | -0.45 |
Clinical Result source | ClinicalTrials.gov NCT02912468 |
Clinical Data Tier / Score | A · 27 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교